the benefits of glp 1 drugs beyond obesity GLP-1-based therapies for diabetes, and GLP-1 receptor agonism: a transformative

However, it remains under investigation whether these benefits are directly due to the GLP-1 agonists or a result of the weight loss they facilitate

Cardiovasc Diabetol 21(1):232 Hu Y et al (2022) Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting

This disease spectrum ranges from isolated lipid deposition within hepatocytes through metabolic dysfunction-associated steatohepatitis (MASH), potentially advancing toward cirrhotic transformation, hepatic functional deterioration, and malignant hepatocellular transformation

Available from

Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis